JATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering
HealthcareNew JerseyPlatform
Apr 16, 2026
Biogen to Acquire Apellis for $5.6B
Announced
HealthcareMassachusettsMerger
Deal Overview
Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion in cash. The deal adds two immune system-regulating products, Syfovre and Empaveli, which launched relatively recently, and brings Apellis talent with nephrology expertise.
Biogen CFO Robin Kramer said the combined cash flow from Biogen and Apellis is expected to support debt leverage ratios and free capacity for other strategic transactions. The acquisition is positioned to complement Biogen’s pipeline, including felzartamab, a drug in testing for uncommon kidney illnesses, and antibody-mediated rejection.
Biogen ended last year with about $4.2 billion in cash and cash equivalents and roughly $6.3 billion in total debt.
Key Details
- Transaction
- Biogen acquires Apellis Pharmaceuticals
- Deal Size
- Over $100M
- Reported Value
- $5.6 billion
Filed under
Powered by Tentt
Source healthcare deals in Massachusetts for your firm
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
WindRose-backed Stellus Rx acquires Tria Health
HealthcareTexasAdd-on
Stellus Rx→Tria Health
Apr 16, 2026
Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility
HealthcareMarylandOther
Emergent BioSolutions
Apr 16, 2026
Medical Technology Associates Announces Acquisition of Stat Biomedical, LLC, Expanding Biomedical Equipment Services - PRWeb
HealthcareFloridaAdd-on
Medical Technology Associates→Stat Biomedical
Apr 16, 2026
Kimberly-Clark keeps Urdaneta as CFO of combined company
HealthcareTexasMerger
Kimberly-Clark→Kenvue
Apr 16, 2026